AR043488A1 - Compuesto de urea, composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimiento para la produccion del mismo y compuesto intermediario de utilidad en este ultimo - Google Patents

Compuesto de urea, composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimiento para la produccion del mismo y compuesto intermediario de utilidad en este ultimo

Info

Publication number
AR043488A1
AR043488A1 ARP040100702A ARP040100702A AR043488A1 AR 043488 A1 AR043488 A1 AR 043488A1 AR P040100702 A ARP040100702 A AR P040100702A AR P040100702 A ARP040100702 A AR P040100702A AR 043488 A1 AR043488 A1 AR 043488A1
Authority
AR
Argentina
Prior art keywords
integer
pain
alkyl
xnr4r5
nr4r5
Prior art date
Application number
ARP040100702A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305291A external-priority patent/GB0305291D0/en
Priority claimed from GB0305290A external-priority patent/GB0305290D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR043488A1 publication Critical patent/AR043488A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)

Abstract

Un compuesto de urea caracterizado porque tiene la fórmula (1) o una sal farmacéuticamente aceptable del mismo, o un solvato del mismo, en el que P y P´ se seleccionan independientemente de arilo y heteroarilo; R1 y R2 se seleccionan independientemente de -H, halo, alquilo, alcoxi, cicloalquilo, aralquilo, aralcoxi, cicloalquilalquilo, cicloalquilalcoxi, -CN, -NO2, -OH, -OCF3, -CF3, -NR4R5, -S(O)mR6, -S(O)2NR4R5, -OS(O)2R6, -OS(O)2CF3, -O(CH2)xNR4R5, -C(O)CF3, -C(O)alquilo, -C(O)cicloalquilo, -C(O)aralquilo, -C(O)Ar, -C(O)(CH2)xOR6, -C(O)(CH2)xNR4R5, -C(O)alcoxi, -C(O)NR4R5, -(CH2)xC(O)alcoxi, -(CH2)xOC(O)R6, -(CH2)xOR6, -(CH2)xNR4R5, -(CH2)xC(O)NR4R5, -(CH2)xN(R4)C(O)R6, -(CH2)xS(O)2NR4R5, -(CH2)xN(R4)S(O)2R6, -ZAr, -(CH2)xS(O)2R6, -(OCH2)xS(O)2R6, -N(R4)S(O)2R6, -N(R4)C(O)R6, o -(CH2)xC(O)alquilo; R4 y R5 pueden ser iguales o diferentes y representan H o alquilo, o R4 y R5, junto con los átomos a los que están unidos, forman un anillo azacicloalcano-(C3-6), (2-oxo)-azacicloalcano-(C3-6), o una cadena de polimetileno -(C5-8), opcionalmente interrumpida por heteroátomos tales como O o NR7; Z representa O, S o NR7; W representa un enlace o un grupo CH o (CH2)CH; R6 representa alquilo o arilo; R7 representa H, alquilo o arilo; m representa un número entero 1 o 2; n representa un número entero 0, 1, 2 o 3; p y Q representan, independientemente, un número entero 0, 1, 2, 3 o 4; cuando W es un enlace, t representa 1, r representa un número entero 0 o 1, y s representa un número entero 0 o 1, de forma que r +s = 1; cuando W es un grupo CH o (CH2)CH, t representa 2, r representa un número entero 0, 1, 2 o 3, y s representa un número entero 0, 1, o 2; y x representa un número entero 0, 1, 2, 3, 4, 5, o 6. Composición farmacéutica que comprende dicho compuesto activo y uso del mismo para preparar un medicamento útil para el tratamiento o la prevención de trastornos en los que el antagonismo del receptor de vanilloides (RV1) es beneficioso. El trastorno preferentemente puede ser dolor, dolor crónico, dolor neuropático, dolor postoperatorio, dolor post-artritis reumatoide, dolor osteoartrósico, dorsalgia, dolor visceral, dolor oncológico, algesia, neuralgia, dolor dental, cefalea, migrana, neuropatías, síndrome del túnel carpiano. Procedimiento para su fabricación y compuesto intermediario útil en el mismo.
ARP040100702A 2003-03-07 2004-03-05 Compuesto de urea, composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimiento para la produccion del mismo y compuesto intermediario de utilidad en este ultimo AR043488A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0305291A GB0305291D0 (en) 2003-03-07 2003-03-07 Novel compounds
GB0305290A GB0305290D0 (en) 2003-03-07 2003-03-07 Novel compounds

Publications (1)

Publication Number Publication Date
AR043488A1 true AR043488A1 (es) 2005-08-03

Family

ID=32964073

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100702A AR043488A1 (es) 2003-03-07 2004-03-05 Compuesto de urea, composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimiento para la produccion del mismo y compuesto intermediario de utilidad en este ultimo

Country Status (6)

Country Link
US (1) US7514562B2 (es)
EP (1) EP1601665A2 (es)
JP (1) JP2006519806A (es)
AR (1) AR043488A1 (es)
TW (1) TW200510370A (es)
WO (1) WO2004078744A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078749A1 (en) 2003-03-06 2004-09-16 Glaxo Group Limited Heterocyclic urea derivatives for the treatment of pain
GB0305426D0 (en) 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
KR20120137420A (ko) * 2004-11-24 2012-12-20 아보트 러보러터리즈 바닐로이드 수용체 아형 1(ｖｒ1) 수용체를 억제하는 크로마닐우레아 화합물 및 이의 용도
RU2450006C2 (ru) 2006-04-18 2012-05-10 Эбботт Лэборетриз Антагонисты ванилоидного рецептора подтипа 1(vr1) и их применение
EP2050734A1 (en) 2006-07-13 2009-04-22 Kyowa Hakko Kirin Co., Ltd. Pentadienamide derivative
JP5934778B2 (ja) * 2011-03-25 2016-06-15 アッヴィ・インコーポレイテッド Ｔｒｐｖ１拮抗薬
US9642859B2 (en) 2012-12-03 2017-05-09 The Board Of Regents Of The University Of Texas System Use of capsazepine and analogs thereof to treat cancer
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424761A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424760A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
JPS5289682A (en) * 1976-01-20 1977-07-27 Pfizer Quinazoline derivatives
GB1561023A (en) 1977-04-22 1980-02-13 Beecham Group Ltd 2-methoxy - 5 - chloro aniline derivatives
ES2007808A6 (es) 1988-03-30 1989-07-01 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de 4-piperidinalquilureas.
IE903196A1 (en) 1989-09-05 1991-03-13 Searle & Co Substituted n-benzylpiperidine amides
FR2675144B1 (fr) * 1991-04-10 1995-06-16 Bouchara Sa Nouvelles quinolones difluorees - leur procede de preparation et les compositions pharmaceutiques en renfermant.
EP0591030A3 (fr) * 1992-09-25 1994-04-27 Sanofi 1-Hétéroaryl-azétidines et -pyrrolidines comme 5-HT3 agonistes
JP3510324B2 (ja) * 1993-05-21 2004-03-29 株式会社日清製粉グループ本社 尿素誘導体
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
DE4319038A1 (de) 1993-06-08 1994-12-15 Bayer Ag Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung
US5925635A (en) * 1996-04-17 1999-07-20 Dupont Pharmaceuticals Company N-(amidinophenyl) cyclourea analogs as factor XA inhibitors
CA2281545C (en) * 1997-02-19 2007-04-24 Berlex Laboratories, Inc. N-heterocyclic derivatives as nos inhibitors
CA2294042A1 (en) * 1997-06-26 1999-01-07 David Kent Herron Antithrombotic agents
CA2294240A1 (en) * 1997-06-26 1999-01-07 Trelia Joyce Craft Antithrombotic agents
WO1999011632A1 (fr) * 1997-09-01 1999-03-11 Kyorin Pharmaceutical Co., Ltd. Derives d'acide quinoxalinecarboxylique disubstitues en position 6,7-asymetrique, sels d'addition de ces derives, et procedes de preparation de ces derives et de ces sels
GB9822440D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
ID29067A (id) 1998-11-20 2001-07-26 Hoffmann La Roche Turunan pirolidina-antagonis reseptor ccr-3
EP1031564A1 (en) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
AU5032400A (en) 1999-05-21 2000-12-12 Wake Forest University Sigma-1 ligands useful for determining the proliferative status of cancer cells
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
KR20020084116A (ko) * 2000-02-07 2002-11-04 애보트 게엠베하 운트 콤파니 카게 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
AU2001261189A1 (en) * 2000-05-03 2001-11-12 Tularik, Inc. Pyrazole antimicrobial agents
WO2002008221A2 (en) * 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
GB0105895D0 (en) * 2001-03-09 2001-04-25 Smithkline Beecham Plc Novel compounds
GB0110901D0 (en) * 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
PE20030417A1 (es) * 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
JPWO2003062234A1 (ja) * 2002-01-23 2005-05-19 山之内製薬株式会社 キノキサリン化合物
GB0203994D0 (en) * 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
AU2003211397A1 (en) 2002-02-27 2003-09-09 Toray Industries, Inc. Cyclic amine compound and ccr3 inhibitory drug containing the same as active ingredient
EP1534681A1 (en) * 2002-06-27 2005-06-01 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
WO2004024710A1 (en) 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
AU2003270186A1 (en) * 2002-09-17 2004-04-08 Actelion Pharmaceuticals Ltd 1-pyridin-4-yl-urea derivatives
WO2004078749A1 (en) 2003-03-06 2004-09-16 Glaxo Group Limited Heterocyclic urea derivatives for the treatment of pain
GB0305426D0 (en) 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
JP2006519806A (ja) 2006-08-31
WO2004078744A3 (en) 2005-01-13
US7514562B2 (en) 2009-04-07
WO2004078744A2 (en) 2004-09-16
US20060276447A1 (en) 2006-12-07
EP1601665A2 (en) 2005-12-07
TW200510370A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
JP6377068B2 (ja) ピラゾロピリミジン化合物
AR084174A1 (es) Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
RU2016143333A (ru) Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение
CN117597327A (zh) 药物制剂
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
NZ595759A (en) Substituted phenylureas and phenylamides as vanilloid receptor ligands
JP2011523412A5 (es)
HN2011000699A (es) El compuesto (s)-1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del acido pirrolidin-1,2-dicarboxilico en forma libre o de sal y composiciones y composicion farmaceutica que lo contiene.
MX2010006421A (es) Compuestos organicos.
TW200734285A (en) Substituted aniline derivatives useful as histamine H3 antagonists
AR038786A1 (es) Compuesto de urea, procedimiento para su preparacion, su uso para fabricar un medicamento y composicion farmaceutica que lo comprende
EA201001848A1 (ru) Производные пиразина в качестве блокаторов эпителиальных натриевых каналов
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
EA201001344A1 (ru) Азотсодержащие бициклические соединения, активные при состояниях хронической боли
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR043488A1 (es) Compuesto de urea, composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimiento para la produccion del mismo y compuesto intermediario de utilidad en este ultimo
AR093937A1 (es) Compuestos quimicos
AR098522A1 (es) Compuesto de triazolo-piridina
AR097199A1 (es) Inhibidores de rorc2 y sus métodos de uso
AR073117A1 (es) Derivado de aminometil-fenil-piperidin-1-il-indolil-metanona, inhibidores de la triptasa de mastocitos, composiciones farmaceuticas que lo contienen, metodo de preparacion, compuestos intermediarios y uso del compuesto en el tratamiento de procesos inflamatorios.
RU2017117559A (ru) Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение
AR088246A1 (es) Derivados de etinilo
PE20142244A1 (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina
JP2015502371A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FA Abandonment or withdrawal
FA Abandonment or withdrawal